7 completed, 2 terminated, 2 unknown, 1 active not recruiting. 14 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 7, Terminated 2, Unknown 2, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 5 | Terminated 2, Unknown 2, Recruiting 1 |
Follow AZD2014: new trials by email Literature Review of AZD2014 trials Research Report on AZD2014
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors Navitoclax, Vistusertib - Metastatic Malignant Solid Neoplasm, Recurrent Lung Small Cell Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 15 | 2018-03-20 | 2023-10-17 |
| A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies acalabrutinib, vistusertib - DLBCL, Richter Syndrome | Phase 1 / Phase 2 | Terminated | Acerta Pharma BV | 25 | 2017-06-29 | 2021-01-06 |
| mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme AZD2014 - Glioblastoma Multiforme | Phase 1 | Completed | Canadian Cancer Trials Group | 15 | 2016-12-22 | 2023-08-04 |
| European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Ribociclib, Topotecan, Temozolomide - Pediatric Cancer | Phase 1 / Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 472 | 2016-08-03 | 2026-07-10 |
| AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma AZD2014, Ibrutinib - Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Module 1: Non-GCB Diffuse Large B-Cell Lymphoma | Phase 1 | Withdrawn | AstraZeneca | 2016-06-01 | 2016-09-15 | |
| Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA) AZD2014, Anastrozole - Endometrial Carcinoma, Metastatic Carcinoma | Phase 1 / Phase 2 | Unknown | Centre Leon Berard | 72 | 2016-04-01 | 2024-02-13 |
| Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer AZD2014, Palbociclib, Fulvestrant - Advanced and Metastatic Breast Cancer | Phase 1 | Completed | AstraZeneca | 54 | 2015-12-07 | 2024-06-06 |
| A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers AZD2014, AZD6244 - Triple-Negative Breast Cancer, Squamous Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | Queen Mary University of London | 118 | 2015-06-01 | 2020-02-25 |
| Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies AZD2014 - Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 28 | 2015-03-17 | 2024-12-17 |
| mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Capivasertib, Laboratory Biomarker Analysis, Olaparib - BRCA1 Mutation Carrier, BRCA2 Mutation Carrier | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 159 | 2014-11-11 | 2026-09-04 |
| Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer AZD2014 - Prostate Cancer | Phase 1 | Completed | Cambridge University Hospitals NHS Foundation Trust | 23 | 2014-10-01 | 2019-07-17 |
| A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel. AZD2014 3 on/4 off & weekly paclitaxel, AZD2014 2 on/5 off & weekly paclitaxel - Advanced Cancer | Phase 1 | Completed | Royal Marsden NHS Foundation Trust | 90 | 2013-04-26 | 2024-09-26 |
| AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer AZD2014, Fulvestrant - Advanced Metastatic Breast Cancer | Phase 1 | Completed | AstraZeneca | 99 | 2012-05-08 | 2026-02-24 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014 AZD2014 - Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 172 | 2009-12-01 | 2016-02-11 |
Neoplasms (3) · Breast Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Carcinoma (1) · Disease (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Glioblastoma (1) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Recurrence (1) · Small Cell Lung Carcinoma (1)
AstraZeneca (5) · Acerta Pharma BV (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Canadian Cancer Trials Group (1) · Centre Leon Berard (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Queen Mary University of London (1) · Royal Marsden NHS Foundation Trust (1)
United Kingdom (7) · United States (5) · France (2) · Canada (1) · Denmark (1) · Italy (1) · Japan (1) · Netherlands (1) · Spain (1)
Anja Wiliams (1) · Birgit Geoerger, MD (1) · Christine L Hann (1) · Dr. Udai Banerji (1) · Elisabeth Oelmann (1) · Ian W Flinn, MD, PhD (1) · Peter Schmid, Professor (1) · Shannon N Westin (1) · Simon C Pacey, MRCP, PhD (1) · Udai Banerji, PhD (1) · Warren Mason (1)
PMID 30016392, PMID 31538815, PMID 31707687, PMID 32379297, PMID 33892407, PMID 34269152, PMID 34347542, PMID 34543871, PMID 35292802, PMID 35551299, PMID 39998620, PMID 41838385, PMID 42686334
2014 (2), 2009 (1), 2015 (1), 2016 (1), P50CA083639 (1), UM1CA186691 (1)